Why don't we know if postbiotics really work?
The biggest gap is the shortage of large, well-designed clinical trials. A 2022 systematic review of 11 randomized controlled trials on postbiotic infant formulas found that 5 had a high risk of bias and 6 had some concerns, meaning the results are not reliable enough to draw firm conclusions [1]. The same review noted that while postbiotic formulas were safe and well tolerated, no clear health benefits were consistently replicated across studies [1]. This pattern holds for other conditions: a 2022 review on postbiotics for childhood diseases found only limited support for treating diarrhea or preventing common infections, and cautioned that the evidence is weak and sometimes biased [12].
Even in promising areas like colorectal cancer, the evidence is mostly preclinical. A 2024 review summarized anti-tumor mechanisms of postbiotic components (e.g., short-chain fatty acids, exopolysaccharides) but relied on animal models and cell studies, not human trials [2]. Without human data, it's impossible to know if these effects translate to real patients. A 2023 review echoed this, stating that postbiotics are currently used only as dietary supplements, not medicines, because clinical evidence is insufficient [5].
What don't we understand about how postbiotics work?
Even when postbiotics show effects, scientists often don't know exactly why. A 2022 review noted that postbiotics can modulate immune response, strengthen the gut barrier, and fight pathogens, but the specific molecules and pathways involved are poorly characterized [8]. Another 2022 review highlighted that postbiotics may modify the host microbiota, but evidence for this is scarce [9]. Without understanding the mechanisms, it's hard to predict which postbiotic will work for which condition, or to standardize production.
The composition of postbiotics also varies widely. They can include inactivated cells, cell fragments, or metabolites like short-chain fatty acids, vitamins, and enzymes [6][8]. A 2023 review pointed out that this diversity makes it difficult to compare studies or establish dose-response relationships [7]. As a 2025 review put it, there is an urgent need for greater clarity and specific regulation to encourage research and development [4].
What's stopping postbiotics from reaching the market?
No government or international agency has yet incorporated the term 'postbiotic' into its regulations, creating a legal gray area for manufacturers [9]. A 2024 review noted that the lack of an effective regulatory framework limits the application of postbiotic products [3]. This means companies cannot make specific health claims, and consumers have no guarantee of quality or efficacy.
Safety is another concern. While postbiotics are generally considered safer than live probiotics (no risk of infection or antibiotic resistance transfer), a 2022 review warned that they could still cause stomach discomfort, sepsis, or toxic shock if not properly assessed [11]. The same review emphasized that safety assessment and quality assurance are critical but often lacking [11]. A 2022 commentary on periodontitis added that most studies on postbiotics for oral health are in rodents or in vitro, with very limited human data [10].
About These Sources
This answer is built on 12 peer-reviewed studies — published from 2022 to 2025, 3 from 2024 or later, 10 in Q1 journals, collectively cited 1,169 times — selected as the most relevant from 14 studies that passed quality screening, drawn from 46 papers retrieved from a database of over 500 million.
Sources used in this answer
Infant Formulas With Postbiotics
A systematic review of 11 RCTs on postbiotic infant formulas found most had high risk of bias or some concerns; formulas were safe but no clear clinical benefits were replicated across studies.
Postbiotics in colorectal cancer: intervention mechanisms and perspectives
A review of postbiotics in colorectal cancer summarized anti-tumor mechanisms (e.g., short-chain fatty acids, exopolysaccharides) but relied on preclinical models, not human trials.
Postbiotics are a candidate for new functional foods
A review highlighted that lack of clinical trial data, mechanism analyses, safety evaluations, and regulatory frameworks limits postbiotic product development.
Postbiotics versus probiotics: Possible new allies for human health
A 2025 review emphasized the urgent need for specific regulation and greater clarity to encourage research and development in the postbiotic sector.
Probiotics, prebiotics, and postbiotics in health and disease
A review noted that probiotics, prebiotics, and postbiotics are currently only dietary supplements, not medicines, due to insufficient clinical evidence.
The Concept of Postbiotics
A review defined postbiotics as preparations of inanimate microorganisms and/or their components that confer a health benefit, and noted the definition encourages innovation.
The Current and Future Perspectives of Postbiotics
A review discussed the diversity of postbiotic components and the difficulty of comparing studies or establishing dose-response relationships.
Postbiotics and Their Health Modulatory Biomolecules
A review identified knowledge gaps in how postbiotics modulate health, including unclear mechanisms for gut barrier strengthening and antimicrobial activity.
Postbiotics: The concept and their use in healthy populations
A review stated that evidence for postbiotics modifying host microbiota is scarce, and no government has incorporated the term into regulation.
Outside the limits of bacterial viability: Postbiotics in the management of periodontitis
A commentary on periodontitis found most postbiotic studies are in rodents or in vitro, with very limited human data, and discussed limitations for clinical translation.
Postbiotics: From emerging concept to application
A review emphasized that safety assessment and quality assurance of postbiotics are critical, as they may cause stomach discomfort, sepsis, or toxic shock.
Evidence on postbiotics in infants and children
A review found only limited support for postbiotic use in treating diarrhea and preventing common pediatric infections, with caution justified due to weak, biased evidence.